Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

CG Oncology (CGON) Gross Profit (2024 - 2025)

CG Oncology filings provide 2 years of Gross Profit readings, the most recent being -$748000.0 for Q4 2025.

  • On a quarterly basis, Gross Profit fell 264.04% to -$748000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$160000.0, a N/A change, with the full-year FY2025 number at -$607000.0, down 153.29% from a year prior.
  • Gross Profit hit -$748000.0 in Q4 2025 for CG Oncology, down from $89000.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $456000.0 in Q4 2024 to a low of -$748000.0 in Q4 2025.